MISSISSAUGA, ONTARIO--(Marketwire - April 13, 2011) - BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) has filed revised financial statements for the third quarter ending September 30, 2010 to include a certificate that the interim financial statements have not been reviewed or audited by external auditors. There have been no changes in the financial statements filed originally on November 24, 2010.
BioSyent Inc. is a publicly traded specialty pharmaceutical company whose wholly owned subsidiary, BioSyent Pharma Inc., sources, acquires or in-licences pharmaceutical products and markets these products in Canada. Wholly owned BioSyent subsidiary Hedley Technologies Ltd. operates the company's legacy business marketing bio and health friendly non-chemical insecticides. BioSyent common shares are listed for trading on the TSX Venture Exchange (TSXV) under the symbol RX.
This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.
The TSX Venture Exchange assumes no responsibility for the accuracy of this release and neither approves nor disapproves of the same.
Contact Information:
Rene C. Goehrum
President and CEO
(905) 206-0013
(905) 206-1413
www.biosyent.com